
ELK Biotechnology c-Myc (phospho Thr58) rabbit pAb
c-Myc (phospho Thr58) rabbit polyclonal antibody로, 인산화된 Thr58 부위를 인식합니다. WB, IHC, IF, IP, ELISA에 사용 가능하며, 인간, 마우스, 랫트에 반응합니다. 세포주기 조절 및 암 관련 연구에 적합합니다.
- 판매단위
- pk
카탈로그
2개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다ELK Biotechnology · ELK Biotechnology c-Myc (phospho Thr58) rabbit pAb
제품명
c-Myc (phospho Thr58) rabbit pAb
제품 정보
| 항목 | 내용 |
|---|---|
| Alternative Names | MYC; BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64 |
| Applications | WB; IHC; IF; IP; ELISA |
| Recommended Dilutions | Western Blot: 1/500 - 1/2000 Immunohistochemistry: 1/100 - 1/300 Immunoprecipitation: 2–5 µg/mg lysate ELISA: 1/10000 Not yet tested in other applications |
| Immunogen | Synthesized peptide derived from human Myc around the phosphorylation site of Thr58 (AA range: 25–74) |
| Host | Rabbit |
| Storage | -20°C / 1 year |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1 mg/ml |
| Observed Band | 50 kDa (also ~60 kDa in some samples) |
| Gene ID (Human) | 4609 |
| Human Swiss-Prot No. | P01106 |
| Cellular Localization | Nucleus, nucleoplasm; Nucleus, nucleolus |
| Species Reactivity | Human; Mouse; Rat |
Background
The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis, and cellular transformation. It functions as a transcription factor regulating specific target genes. Mutations, overexpression, rearrangement, and translocation of this gene have been associated with various hematopoietic tumors, leukemias, and lymphomas, including Burkitt lymphoma.
Alternative translation initiation from upstream non-AUG (CUG) and downstream AUG start sites produces two isoforms with distinct N-termini. The non-AUG initiated isoform synthesis is suppressed in Burkitt’s lymphomas, suggesting its importance in normal gene function.
[Provided by RefSeq, Jul 2008]
ELK Biotechnology 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.
